{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T17:40:14Z","timestamp":1775238014790,"version":"3.50.1"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Science and Technology Development Fund, Egypt (STDF) administered through Basic and Applied Research Grants","award":["STDF 3130"],"award-info":[{"award-number":["STDF 3130"]}]},{"DOI":"10.13039\/501100003009","name":"STDF","doi-asserted-by":"publisher","award":["2339"],"award-info":[{"award-number":["2339"]}],"id":[{"id":"10.13039\/501100003009","id-type":"DOI","asserted-by":"publisher"}]},{"name":"STDF-RSDTG","award":["6901"],"award-info":[{"award-number":["6901"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.ejmech.2018.01.072","type":"journal-article","created":{"date-parts":[[2018,2,2]],"date-time":"2018-02-02T08:30:41Z","timestamp":1517560241000},"page":"687-708","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Part III: Novel checkpoint kinase 2 (Chk2) inhibitors; design, synthesis and biological evaluation of pyrimidine-benzimidazole conjugates"],"prefix":"10.1016","volume":"146","author":[{"given":"Shadia A.","family":"Galal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad","family":"Khattab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samia A.","family":"Shouman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raghda","family":"Ramadan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omaima M.","family":"Kandil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omnia M.","family":"Kandil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashraf","family":"Tabll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasmine S.","family":"El Abd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reem","family":"El-Shenawy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasmin M.","family":"Attia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed A.","family":"El-Rashedy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hoda I.","family":"El Diwani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2018.01.072_bib1","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/nature01322","article-title":"Inflammation and cancer","volume":"420","author":"Coussens","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2018.01.072_bib2","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.cell.2010.01.025","article-title":"Immunity, inflammation, and cancer","volume":"140","author":"Grivennikov","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2018.01.072_bib3","article-title":"Removal of oxidatively generated DNA damage by overlapping repair pathways","author":"Shafirovich","year":"2016","journal-title":"Free Radic. Biol."},{"key":"10.1016\/j.ejmech.2018.01.072_bib4","series-title":"Manual of Clinical Oncology","first-page":"46","year":"2009"},{"key":"10.1016\/j.ejmech.2018.01.072_bib5","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1038\/nature03160","article-title":"Genome-wide survey of protein kinases required for cell cycle progression","volume":"432","author":"Bettencourt-Dias","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2018.01.072_bib6","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1038\/nm0804-786","article-title":"Treating cancer's kinase\u2017addiction","volume":"10","author":"Baselga","year":"2004","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2018.01.072_bib7","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/nrd773","article-title":"Protein kinases\u2014the major drug targets of the twenty-first century?","volume":"1","author":"Cohen","year":"2002","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2018.01.072_bib8","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1038\/sj.bjc.6602051","article-title":"Dual blockade of EGFR and ERK1\/2 phosphorylation potentiates growth inhibition of breast cancer cells","volume":"91","author":"Lev","year":"2004","journal-title":"Br. J. Canc."},{"key":"10.1016\/j.ejmech.2018.01.072_bib9","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/nature03097","article-title":"Cell-cycle checkpoints and cancer","volume":"432","author":"Kastan","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2018.01.072_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pbio.1000287","article-title":"A\u00a0mitotic phosphorylation feedback network connects Cdk1, Plk1, 53BP1, and Chk2 to inactivate the g2\/m DNA damage checkpoint","volume":"8","author":"Van Vugt","year":"2010","journal-title":"PLoS Biol."},{"key":"10.1016\/j.ejmech.2018.01.072_bib11","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.dnarep.2004.04.002","article-title":"PI 3-kinase related kinases: big\u2018 players in stress-induced signaling pathways","volume":"3","author":"Abraham","year":"2004","journal-title":"DNA Repair"},{"key":"10.1016\/j.ejmech.2018.01.072_bib12","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1038\/onc.2010.40","article-title":"p53-Mediated transactivation of LIMK2b links act in dynamics to cell cycle checkpoint control","volume":"29","author":"Hsu","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2018.01.072_bib13","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1126\/science.282.5395.1893","article-title":"Linkage of ATM to cell cycle regulation by the Chk2 protein kinase","volume":"282","author":"Matsuoka","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2018.01.072_bib14","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.tibs.2006.05.004","article-title":"The ATM-mediated DNA-damage response: taking shape,","volume":"31","author":"Shiloh","year":"2006","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.ejmech.2018.01.072_bib15","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S1535-6108(03)00110-7","article-title":"Chk1 and Chk2 kinases in checkpoint control and cancer","volume":"3","author":"Bartek","year":"2003","journal-title":"Canc. Cell"},{"key":"10.1016\/j.ejmech.2018.01.072_bib16","doi-asserted-by":"crossref","first-page":"3411","DOI":"10.1038\/sj.emboj.7600812","article-title":"ATM and Chk2-dependent phosphorylation of MDMX contribute to p53 activation after DNA damage","volume":"24","author":"Chen","year":"2005","journal-title":"EMBO J."},{"key":"10.1016\/j.ejmech.2018.01.072_bib17","doi-asserted-by":"crossref","first-page":"9608","DOI":"10.1128\/MCB.25.21.9608-9620.2005","article-title":"DNA damage-induced phosphorylation of MdmX at serine 367 activates p53 by targeting MdmX for Mdm2-dependent degradation","volume":"25","author":"Okamoto","year":"2005","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2018.01.072_bib18","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/ncb974","article-title":"Chk2 activates E2F-1 in response to DNA damage","volume":"5","author":"Stevens","year":"2003","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.ejmech.2018.01.072_bib19","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1128\/MCB.24.7.2968-2977.2004","article-title":"Apoptosis associated with deregulated E2F activity is dependent on E2F1 and Atm\/Nbs1\/Chk2","volume":"24","author":"Rogoff","year":"2004","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2018.01.072_bib20","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1038\/onc.2008.477","article-title":"The cell cycle checkpoint kinase CHK2 mediates DNA damage induced stabilization of TTK\/hMps1","volume":"28","author":"Yeh","year":"2009","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2018.01.072_bib21","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1158\/1078-0432.CCR-06-0743","article-title":"Chk2 molecular interaction map and rationale for Chk2 inhibitors","volume":"12","author":"Pommier","year":"2006","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.ejmech.2018.01.072_bib22","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1038\/nrc2251","article-title":"Chk2 kinase: cancer susceptibility and cancer therapy - two sides of the same coin?","volume":"7","author":"Antoni","year":"2007","journal-title":"Nat. Rev. Canc."},{"key":"10.1016\/j.ejmech.2018.01.072_bib23","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.2174\/092986707780362844","article-title":"Enhancing the efficacy of chemotherapeutic drugs by small molecule inhibition of nf-kappab and checkpoint kinases","volume":"14","author":"Sharma","year":"2007","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.01.072_bib24","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.dnarep.2004.03.033","article-title":"The Chk2 protein kinase","volume":"3","author":"Ahn","year":"2004","journal-title":"DNA Repair"},{"key":"10.1016\/j.ejmech.2018.01.072_bib25","doi-asserted-by":"crossref","first-page":"9152","DOI":"10.1158\/0008-5472.CAN-04-2727","article-title":"Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM","volume":"64","author":"Hickson","year":"2004","journal-title":"Canc. Res."},{"key":"10.1016\/j.ejmech.2018.01.072_bib26","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1124\/mol.107.035832","article-title":"Identification of a bis-guanylhydrazone [4,4-Diacetyldiphenylureabis(guanylhydrazone); NSC 109555] as a novel chemotype for inhibition of Chk2 kinase","volume":"72","author":"Jobson","year":"2007","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejmech.2018.01.072_bib27","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/1741-7007-8-63","article-title":"Altered cell cycle regulation helps stem-like carcinoma cells resist apoptosis","volume":"8","author":"Chappell","year":"2010","journal-title":"BMC Biol."},{"key":"10.1016\/j.ejmech.2018.01.072_bib28","doi-asserted-by":"crossref","first-page":"4353","DOI":"10.1038\/sj.onc.1207573","article-title":"The cell cycle checkpoint kinase Chk2 is a negative regulator of mitotic catastrophe","volume":"23","author":"Castedo","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2018.01.072_bib29","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.pharmthera.2016.02.003","article-title":"Turchi, J. J. DNA repair targeted therapy: the past or future of cancer treatment?","volume":"160","author":"Gavande","year":"2016","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2018.01.072_bib30","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1038\/35103059","article-title":"Chk2 kinase \u2014 a busy messenger","volume":"2","author":"Bartek","year":"2001","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2018.01.072_bib31","doi-asserted-by":"crossref","DOI":"10.1021\/jm0495935","article-title":"Checkpoint kinase inhibitors: SAR and 59 radioprotective properties of a series of 2-arylbenzimidazoles","volume":"48","author":"Arienti","year":"2005","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.01.072_bib32","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1016\/j.bmcl.2005.12.096","article-title":"Novel non-benzimidazole chk2 kinase inhibitors","volume":"16","author":"McClure","year":"2006","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2018.01.072_bib33","doi-asserted-by":"crossref","first-page":"6467","DOI":"10.1016\/j.bmcl.2007.09.098","article-title":"2-Aryl benzimidazoles featuring alkyl-linked pendant alcohols and amines as inhibitors of checkpoint kinase Chk2","volume":"17","author":"Neff","year":"2007","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2018.01.072_bib34","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1021\/jm101150b","article-title":"Structure-based design of potent and selective 2-(quinazolin-2- yl)phenol inhibitors of checkpoint kinase 2","volume":"54","author":"Caldwell","year":"2011","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.01.072_bib35","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.ejmech.2017.03.090","article-title":"Part I: design, synthesis and biological evaluation of novel pyrazole-benzimidazole conjugates as checkpoint kinase 2 (Chk2) inhibitors with studying their activities alone and in combination with genotoxic drugs","volume":"134","author":"Galal","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.01.072_bib36","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.ejmech.2017.12.023","article-title":"Part II: new candidates of pyrazole-benzimidazole conjugates as checkpoint kinase 2 (Chk2) inhibitors","volume":"144","author":"Galal","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.01.072_bib37","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.bmc.2011.12.054","article-title":"Synthesis and evaluation of debromohymenialdisine derived Chk2 inhibitors","volume":"20","author":"Saleem","year":"2012","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.01.072_bib38","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1016\/j.ejmech.2010.02.011","article-title":"Novel benzimidazole-pyrimidine conjugates as potent antitumor agents","volume":"45","author":"Abdel-Mohsen","year":"2010","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.01.072_bib39","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.ejmech.2010.11.022","article-title":"Part I: synthesis, cancer chemopreventive activity and molecular docking study of novel quinoxaline derivatives","volume":"46","author":"Galal","year":"2011","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.01.072_bib40","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/j.ejmech.2016.11.028","article-title":"Novel pyrimidine-2,4-dione\u20131,2,3-triazole and furo[2,3-d]pyrimidine-2-one\u20131,2,3- triazole hybrids as potential anti-cancer agents: synthesis, computational and X-ray analysis and biological evaluation","volume":"125","author":"Gregori\u0107","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.01.072_bib41","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1021\/jm301859s","article-title":"Discovery of 4-{4-[(3R)-3-Methylmorpholin-4-yl]-6-[1-(methylsulfonyl)cyclopropyl] pyrimidin-2-y l}-1H-indole (AZ20): a potent and selective inhibitor of ATR protein kinase with monotherapy in\u00a0vivo antitumor activity","volume":"56","author":"Foote","year":"2013","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.01.072_bib42","doi-asserted-by":"crossref","first-page":"44289","DOI":"10.18632\/oncotarget.6247","article-title":"The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the antitumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in\u00a0vivo","volume":"6","author":"Vendetti","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2018.01.072_bib43","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.2174\/092986707781058805","article-title":"Molecular hybridization: a useful tool in the design of new drug prototypes","volume":"14","author":"Viegas-Junior","year":"2007","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.01.072_bib44","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1517\/17460440903341705","article-title":"Promise and challenges in drug discovery and development of hybrid anticancer drugs","volume":"4","author":"Gediya","year":"2009","journal-title":"Expet Opin. Drug Discov."},{"key":"10.1016\/j.ejmech.2018.01.072_bib45","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/j.ejmech.2017.10.021","article-title":"Dual or multi-targeting inhibitors: the next generation anticancer agents","volume":"143","author":"Raghavendra","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.01.072_bib46","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1093\/jnci\/82.13.1107","article-title":"New colorimetric cytotoxicity assay for anticancer-drug screening","volume":"82","author":"Skehan","year":"1990","journal-title":"J.\u00a0Natl. Cancer Inst."},{"key":"10.1016\/j.ejmech.2018.01.072_bib47","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1517\/13543770802653622","article-title":"Checkpoint kinase inhibitors: a review of the patent literature","volume":"19","author":"Janetka","year":"2009","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ejmech.2018.01.072_bib48","doi-asserted-by":"crossref","first-page":"4129","DOI":"10.1128\/MCB.21.13.4129-4139.2001","article-title":"ATR-mediated checkpoint pathways regulate phosphorylation and activation of human Chk1","volume":"21","author":"Zhao","year":"2001","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2018.01.072_bib49","first-page":"1","article-title":"The role of wild-type p53 in cisplatin-induced Chk2 phosphorylation and the inhibition of platinum resistance with a Chk2 inhibitor","volume":"2011","author":"Liang","year":"2010","journal-title":"Chemother. Res. Pract."},{"key":"10.1016\/j.ejmech.2018.01.072_bib50","doi-asserted-by":"crossref","first-page":"7265","DOI":"10.1038\/sj.onc.1206933","article-title":"Cisplatin: mode of cytotoxic action and molecular basis of resistance","volume":"22","author":"Siddik","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2018.01.072_bib51","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1158\/1535-7163.MCT-06-0567","article-title":"Biochemical and cellular characterization of VRX0466617, a novel and selective inhibitor for the checkpoint kinase Chk2","volume":"6","author":"Carlessi","year":"2007","journal-title":"Mol. Canc. Therapeut."},{"key":"10.1016\/j.ejmech.2018.01.072_bib52","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1124\/jpet.109.154997","article-title":"Cellular inhibition of checkpoint kinase 2 (Chk2) and potentiation of camptothecins and radiation by the novel Chk2 inhibitor PV1019 [7-nitro-1H-indole-2-carboxylic acid {4-[1-(guanidinohydrazone)-ethyl]-phenyl}-amide]","volume":"331","author":"Jobson","year":"2009","journal-title":"J.\u00a0Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejmech.2018.01.072_bib53","doi-asserted-by":"crossref","first-page":"4350","DOI":"10.1073\/pnas.76.9.4350","article-title":"A\u00a0method has been devised for the electrophoretic transfer of proteins","volume":"76","author":"Towbin","year":"1979","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejmech.2018.01.072_bib54","series-title":"Molecular Operating Environment (MOE) 2008.10","year":"2008"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523418300850?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523418300850?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,9]],"date-time":"2019-08-09T04:39:21Z","timestamp":1565325561000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523418300850"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":54,"alternative-id":["S0223523418300850"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2018.01.072","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Part III: Novel checkpoint kinase 2 (Chk2) inhibitors; design, synthesis and biological evaluation of pyrimidine-benzimidazole conjugates","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2018.01.072","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}